Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report | Synapse
March 3, 2026Open Access
Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report
Key Points
Resolution of high-risk basal cell carcinoma was achieved using eribulin, a microtubule-targeting agent.
The treatment resulted in significant tumor shrinkage, showcasing eribulin's potential in BCC management.
Observational analysis provided insights into chemotherapy options for managing challenging cases of basal cell carcinoma.
Highlights the need for further exploration of microtubule-targeting agents in the treatment of skin cancers.